Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer
To evaluate the tolerance, safety, pharmacokinetics, and preliminary anti-tumor activity of QLH12016 in patients with metastatic castration resistant prostate cancer
Prostate Cancer
DRUG: QLH12016
Arm A： Incidence of Dose Limiting Toxicities, First Cycle Dose limiting toxicities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drug, 28 Days|Arm A：Maximum Tolerated Dose, The Maximum Tolerated Dose determined by the Incidence of Dose Limiting Toxicities, 28 Days|Arm A：Recommended Phase 2 Dose, Recommended Phase 2 Dose determined by the frequency of Incidence of Dose Limiting Toxicities, 28 Days|Arm A：AE, The incidence, severity and correlation with the study drug of adverse events (AEs) evaluated according to the National Cancer Institute (NCI) - General Terminology of Adverse Events (CTCAE) Version 5.0, 20 weeks|Arm A：SAE, The incidence, severity and correlation with the study drug of Serious adverse event (SAE) evaluated according to the National Cancer Institute (NCI) - General Terminology of Adverse Events (CTCAE) Version 5.0, 20 weeks|Arm B-D：PSA Response Rate, a decrease of ≥ 50% in PSA levels from baseline to baseline, and reassessed PSA relief after ≥ 3 weeks in each arm, 20 weeks|Arm B-D：Objective Response Rate, the percentage of "CR/PR" subjects in each arm, 20 weeks
Cmax, The highest plasma drug concentration, 20 weeks|Tmax, The time blood drug concentration reaching Cmax, 20 weeks|AUC, The area enclosed by the drug time curve and the time axis, 20 weeks|Arm A：ORR, the percentage of "CR/PR" subjects, 20 weeks|Arm A：PSA Response Rate, a decrease of ≥ 50% in PSA levels from baseline to baseline, and reassessed PSA relief after ≥ 3 weeks, 20 weeks|Arm B-D：AE, The incidence, severity and correlation with the study drug of adverse events (AEs) evaluated according to the National Cancer Institute (NCI) - General Terminology of Adverse Events (CTCAE) Version 5.0, 20 weeks|Arm B-D：SAE, The incidence, severity and correlation with the study drug of Serious adverse event (SAE) evaluated according to the National Cancer Institute (NCI) - General Terminology of Adverse Events (CTCAE) Version 5.0, 20 weeks|DOR, The time between the initial evaluation of CR or PR and disease progression, 20 weeks|DCR, the percentage of "CR/PR/SD" subjects, 20 weeks|rPFS, The time between the first administration of the investigational drug and the first recording of disease progression (determined according to RECIST v1.1 and PCWG3) or the date of all-cause death (whichever occurs first), 20 weeks|OS, The time between the first trial drug administration and patient death due to various reasons, 20 weeks
Biomarkers, Using next-generation sequencing，reverse transcription DNA and quantitative polymerase chain reaction to evaluate tumor mutational burden and other signal pathway indicators, 20 weeks
Subjects will use QLH12016 for the treatment of mCRPC.